Table 1.
Clinical characteristics of patients
| Variable | n | % | median | range | |
|---|---|---|---|---|---|
| Age (years) | 68 | 58-80 | |||
| PSAi (ng/ml) | 12.0 | 1.9-48.7 | |||
| Clinical Stage | T1C | 26 | 66.7 | ||
| ≥ T2a | 13 | 33.3 | |||
| Gleason Score | ≤ 6 | 3 | 7.7 | ||
| 7 | 28 | 71.8 | |||
| ≥ 8 | 8 | 20.5 | |||
| Risk Group | IR | 16 | 41.0 | ||
| HR | 23 | 59.0 | |||
| Comorbidities* | No | 25 | 64.1 | ||
| HTN | 6 | 15.3 | |||
| CAD | 5 | 12.8 | |||
| DM | 7 | 17.9 | |||
| Two or + | 4 | 10.3 | |||
| Total | 39 | 100.0 |
PSAi: initial PSA value; IR: intermediate risk for biochemical failure; HR: high risk for biochemical failure; HTN: systemic arterial hypertension; CAD: coronary arterial disease; DM: diabetes mellitus. * Sum adds more than 100% in this column because some patients presented with more than one associated comorbidity.